AN2 Therapeutics
ANTX
31 hedge funds and large institutions have $100M invested in AN2 Therapeutics in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 16 reducing their positions, and 14 closing their positions.
183% more capital inflows, than outflows
Capital inflows: $23.1M | Capital outflows: $8.17M
10.94% more ownership
Funds ownership: 49.49% → 60.43% (+11%)
18% less funds holding
Funds holding: 38 → 31 (-7)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
81% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCG Crossover Management
Palo Alto,
California
|
+$9.27M |
| 2 |
Janus Henderson Group
London,
|
+$7.19M |
| 3 |
Octagon Capital Advisors
New York
|
+$5.18M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$359K |
| 5 |
Private Advisor Group
Morristown,
New Jersey
|
+$327K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.31M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$751K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$661K |
| 4 |
State Street
Boston,
Massachusetts
|
-$566K |
| 5 |
Avidity Partners Management
Dallas,
Texas
|
-$475K |
ANTX Hedge Fund Activity: Q2 2023 in Review
31 of the 6,390 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q2 2023, worth a combined $100M — up 5.4% from $94.8M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ANTX and 8 opened new positions — a net loss of 6 holders — while 16 trimmed existing stakes and 3 added.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $9.27M. The largest seller was BlackRock, cutting an estimated $3.31M.
- 31 institutional investors held AN2 Therapeutics (ANTX) as of Q2 2023, down from 38 in Q1 2023.
- Funds reported $100M of AN2 Therapeutics stock for Q2 2023, up 5.4% quarter-over-quarter.
- 8 funds opened new AN2 Therapeutics positions in Q2 2023 and 14 closed out, a net change of -6 holders.
- The largest AN2 Therapeutics buyer in Q2 2023 was TCG Crossover Management, an estimated $9.27M added.
- The largest AN2 Therapeutics seller in Q2 2023 was BlackRock, an estimated $3.31M sold.
Based on aggregated 13F filings for Q2 2023.